ParkinsonCanadaV1, Main, Exploration, bibRecord, 002081

Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients

Identifieur interne : 002081 ( Main/Exploration ); précédent : 002080; suivant : 002082

Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients

Auteurs : Pershia Samadi [Canada] ; Alex Rajput [Canada] ; Frédéric Calon [Canada] ; Laurent Gregoire [Canada] ; Oleh Homykiewicz [Canada, Autriche] ; Ali H. Rajput [Canada] ; Thèrèse Di Paolo [Canada]

Source :

Journal of neuropathology and experimental neurology [ 0022-3069 ] ; 2009.

RBID : Pascal:09-0181756

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Dyskinésie, Pathologie du système nerveux, Récepteur métabotropique, Récepteur glutamate, Encéphale, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Amino Acids (pharmacology), Antiparkinson Agents (adverse effects), Brain (drug effects), Brain (metabolism), Brain (pathology), Cocaine (analogs & derivatives), Dyskinesia, Dyskinesia, Drug-Induced (etiology), Dyskinesia, Drug-Induced (pathology), Encephalon, Excitatory Amino Acid Antagonists (pharmacology), Female, Glutamate receptor, Human, Humans, Iodine Radioisotopes, Levodopa (adverse effects), Male, Metabotropic receptor, Nervous system diseases, Parkinson disease, Parkinsonian Disorders (drug therapy), Parkinsonian Disorders (pathology), Postmortem Changes, Radioligand Assay, Receptors, Metabotropic Glutamate (metabolism), Tritium (pharmacology), Xanthenes (pharmacology).
MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , analogs & derivatives : Cocaine.
- chemical , metabolism : Receptors, Metabotropic Glutamate.
- chemical , pharmacology : Amino Acids, Excitatory Amino Acid Antagonists, Tritium, Xanthenes.
- drug effects : Brain.
- drug therapy : Parkinsonian Disorders.
- etiology : Dyskinesia, Drug-Induced.
- metabolism : Brain.
- pathology : Brain, Dyskinesia, Drug-Induced, Parkinsonian Disorders.
- Aged, Aged, 80 and over, Female, Humans, Iodine Radioisotopes, Male, Postmortem Changes, Radioligand Assay.

Abstract

Modulation of basal ganglia group II metabotropic glutamate receptors (mGluR2/3) is a potential therapeutic alternative to levodopa in Parkinson disease (PD). We used receptor-binding autoradiography of the mGluR2/3-selective radioligand [³H]LY341495 in post-mortem brain specimens from PD patients (n = 14) and controls (n = 11) to investigate possible contributions of changes in ligand binding of this receptor to levodopa-associated motor complications experienced premortem in PD patients. The PD patients included those with and without histories of dyskinesias and those with and without "wearing off," which is defined as a reduced period of benefit from levodopa. Specific binding of [³H]LY341495 to mGluR2/3 in the basal ganglia was higher in the caudate nucleus than the putamen and lower by approximately half in the external and internal globus pallidus (GPi) in controls. [³H]LY341495-specific binding was reduced in the caudate and GPi in patients without wearing-off (-22% caudate, -30% GPi), compared with controls and with patients who had experienced wearing-off; there were no differences among PD patients with or without dyskinesias. These data suggest that an adaptive downregulation of mGluR2/3 in PD patients without wearing-off may compensate for increased glutamate. They indicate a key role for mGluR2/3 in control of movement and the potential for mGluR2/3-targeted drugs in the management of wearing-off fluctuations in PD.

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients</title>
<author><name sortKey="Samadi, Pershia" sort="Samadi, Pershia" uniqKey="Samadi P" first="Pershia" last="Samadi">Pershia Samadi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Alex" sort="Rajput, Alex" uniqKey="Rajput A" first="Alex" last="Rajput">Alex Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gregoire, Laurent" sort="Gregoire, Laurent" uniqKey="Gregoire L" first="Laurent" last="Gregoire">Laurent Gregoire</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Homykiewicz, Oleh" sort="Homykiewicz, Oleh" uniqKey="Homykiewicz O" first="Oleh" last="Homykiewicz">Oleh Homykiewicz</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Institute for Brain Research, Faculty of Medicine, University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thèrèse" last="Di Paolo">Thèrèse Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0181756</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0181756 INIST</idno>
<idno type="RBID">Pascal:09-0181756</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000554</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000738</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000436</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000436</idno>
<idno type="wicri:doubleKey">0022-3069:2009:Samadi P:metabotropic:glutamate:receptor</idno>
<idno type="wicri:Area/Main/Merge">002240</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:19287314</idno>
<idno type="wicri:Area/PubMed/Corpus">000E87</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E87</idno>
<idno type="wicri:Area/PubMed/Curation">000E87</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E87</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000E87</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E87</idno>
<idno type="wicri:Area/Ncbi/Merge">000A48</idno>
<idno type="wicri:Area/Ncbi/Curation">000A48</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000A48</idno>
<idno type="wicri:doubleKey">0022-3069:2009:Samadi P:metabotropic:glutamate:receptor</idno>
<idno type="wicri:Area/Main/Merge">001F64</idno>
<idno type="wicri:Area/Main/Curation">002081</idno>
<idno type="wicri:Area/Main/Exploration">002081</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients</title>
<author><name sortKey="Samadi, Pershia" sort="Samadi, Pershia" uniqKey="Samadi P" first="Pershia" last="Samadi">Pershia Samadi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Rajput, Alex" sort="Rajput, Alex" uniqKey="Rajput A" first="Alex" last="Rajput">Alex Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gregoire, Laurent" sort="Gregoire, Laurent" uniqKey="Gregoire L" first="Laurent" last="Gregoire">Laurent Gregoire</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Homykiewicz, Oleh" sort="Homykiewicz, Oleh" uniqKey="Homykiewicz O" first="Oleh" last="Homykiewicz">Oleh Homykiewicz</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Institute for Brain Research, Faculty of Medicine, University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thèrèse" last="Di Paolo">Thèrèse Di Paolo</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Molecular Endocrinology and Oncology Research Centre, Laval University Medical Centre</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Faculty of Pharmacy, Laval University</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurology, University of Saskatchewan, Royal University Hospital</s1>
<s2>Saskatoon</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of neuropathology and experimental neurology</title>
<title level="j" type="abbreviated">J. neuropathol. exp. neurol.</title>
<idno type="ISSN">0022-3069</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of neuropathology and experimental neurology</title>
<title level="j" type="abbreviated">J. neuropathol. exp. neurol.</title>
<idno type="ISSN">0022-3069</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Amino Acids (pharmacology)</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Brain (drug effects)</term>
<term>Brain (metabolism)</term>
<term>Brain (pathology)</term>
<term>Cocaine (analogs & derivatives)</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Dyskinesia, Drug-Induced (pathology)</term>
<term>Encephalon</term>
<term>Excitatory Amino Acid Antagonists (pharmacology)</term>
<term>Female</term>
<term>Glutamate receptor</term>
<term>Human</term>
<term>Humans</term>
<term>Iodine Radioisotopes</term>
<term>Levodopa (adverse effects)</term>
<term>Male</term>
<term>Metabotropic receptor</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Parkinsonian Disorders (pathology)</term>
<term>Postmortem Changes</term>
<term>Radioligand Assay</term>
<term>Receptors, Metabotropic Glutamate (metabolism)</term>
<term>Tritium (pharmacology)</term>
<term>Xanthenes (pharmacology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Cocaine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Metabotropic Glutamate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amino Acids</term>
<term>Excitatory Amino Acid Antagonists</term>
<term>Tritium</term>
<term>Xanthenes</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Brain</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term>
<term>Dyskinesia, Drug-Induced</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Female</term>
<term>Humans</term>
<term>Iodine Radioisotopes</term>
<term>Male</term>
<term>Postmortem Changes</term>
<term>Radioligand Assay</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Dyskinésie</term>
<term>Pathologie du   système nerveux</term>
<term>Récepteur métabotropique</term>
<term>Récepteur glutamate</term>
<term>Encéphale</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Modulation of basal ganglia group II metabotropic glutamate receptors (mGluR2/3) is a potential therapeutic alternative to levodopa in Parkinson disease (PD). We used receptor-binding autoradiography of the mGluR2/3-selective radioligand [<sup>3</sup>
H]LY341495 in post-mortem brain specimens from PD patients (n = 14) and controls (n = 11) to investigate possible contributions of changes in ligand binding of this receptor to levodopa-associated motor complications experienced premortem in PD patients. The PD patients included those with and without histories of dyskinesias and those with and without "wearing off," which is defined as a reduced period of benefit from levodopa. Specific binding of [<sup>3</sup>
H]LY341495 to mGluR2/3 in the basal ganglia was higher in the caudate nucleus than the putamen and lower by approximately half in the external and internal globus pallidus (GPi) in controls. [<sup>3</sup>
H]LY341495-specific binding was reduced in the caudate and GPi in patients without wearing-off (-22% caudate, -30% GPi), compared with controls and with patients who had experienced wearing-off; there were no differences among PD patients with or without dyskinesias. These data suggest that an adaptive downregulation of mGluR2/3 in PD patients without wearing-off may compensate for increased glutamate. They indicate a key role for mGluR2/3 in control of movement and the potential for mGluR2/3-targeted drugs in the management of wearing-off fluctuations in PD.</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
<li>Canada</li>
</country>
<region><li>Vienne (Autriche)</li>
</region>
<settlement><li>Vienne (Autriche)</li>
</settlement>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Samadi, Pershia" sort="Samadi, Pershia" uniqKey="Samadi P" first="Pershia" last="Samadi">Pershia Samadi</name>
</noRegion>
<name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name>
<name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thèrèse" last="Di Paolo">Thèrèse Di Paolo</name>
<name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thèrèse" last="Di Paolo">Thèrèse Di Paolo</name>
<name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thèrèse" last="Di Paolo">Thèrèse Di Paolo</name>
<name sortKey="Gregoire, Laurent" sort="Gregoire, Laurent" uniqKey="Gregoire L" first="Laurent" last="Gregoire">Laurent Gregoire</name>
<name sortKey="Homykiewicz, Oleh" sort="Homykiewicz, Oleh" uniqKey="Homykiewicz O" first="Oleh" last="Homykiewicz">Oleh Homykiewicz</name>
<name sortKey="Rajput, Alex" sort="Rajput, Alex" uniqKey="Rajput A" first="Alex" last="Rajput">Alex Rajput</name>
<name sortKey="Rajput, Ali H" sort="Rajput, Ali H" uniqKey="Rajput A" first="Ali H." last="Rajput">Ali H. Rajput</name>
<name sortKey="Samadi, Pershia" sort="Samadi, Pershia" uniqKey="Samadi P" first="Pershia" last="Samadi">Pershia Samadi</name>
</country>
<country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Homykiewicz, Oleh" sort="Homykiewicz, Oleh" uniqKey="Homykiewicz O" first="Oleh" last="Homykiewicz">Oleh Homykiewicz</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002081 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002081 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:09-0181756
   |texte=   Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients

Metabotropic Glutamate Receptor II in the Brains of Parkinsonian Patients

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.